Hikma Pharmaceuticals (HIK) News Today GBX 1,994 -2.00 (-0.10%) As of 05:27 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average - Should You Sell?Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200 Day Moving Average - What's Next?March 26 at 2:39 AM | marketbeat.comHikma Pharmaceuticals announces Health Canada approval of KLOXXADO nasal sprayMarch 20, 2025 | markets.businessinsider.comHikma Pharmaceuticals PLC (LON:HIK) Increases Dividend to $0.48 Per ShareHikma Pharmaceuticals PLC (LON:HIK) announced a dividend on Wednesday, February 26th. Stockholders of record on Thursday, March 20th will be given a dividend of $0.48 per share on Thursday, May 1st. This represents a dividend yield of 1.8%. The ex-dividend date is Thursday, March 20th. This is a 50.0% increase from Hikma Pharmaceuticals's previous dividend of $0.32. The official announcement can be accessed at this link.March 19, 2025 | marketbeat.comShould Income Investors Look At Hikma Pharmaceuticals PLC (LON:HIK) Before Its Ex-Dividend?March 16, 2025 | finance.yahoo.comHikma Pharmaceuticals slips Thursday, underperforms marketMarch 13, 2025 | marketwatch.comHikma Pharmaceuticals (LON:HIK) Earns "Buy" Rating from Berenberg BankBerenberg Bank reiterated a "buy" rating and set a GBX 2,560 ($33.14) price objective on shares of Hikma Pharmaceuticals in a research report on Monday.March 13, 2025 | marketbeat.comHikma races to launch generic versions of blockbuster obesity drugsMarch 9, 2025 | ft.comHikma Pharmaceuticals' (HIK) "Overweight" Rating Reaffirmed at JPMorgan Chase & Co.JPMorgan Chase & Co. reissued an "overweight" rating on shares of Hikma Pharmaceuticals in a report on Friday.March 7, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200 Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?March 1, 2025 | marketbeat.comRBC Capital Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)February 27, 2025 | markets.businessinsider.comHikma Pharmaceuticals (HIK) Receives a Buy from J.P. MorganFebruary 27, 2025 | markets.businessinsider.comHikma Pharmaceuticals reports 'strong' 2024 results with 9% revenue growthFebruary 26, 2025 | msn.comHikma Pharmaceuticals slides Wednesday, underperforms marketFebruary 26, 2025 | marketwatch.comHikma shares fall as margins disappoint, despite revenue beatFebruary 26, 2025 | investing.comHikma Pharmaceuticals Reports Strong 2024 Results with 9% Revenue GrowthFebruary 26, 2025 | msn.comHikma’s profit jumps as demand for generic medicines boomsFebruary 26, 2025 | msn.comHikma Pharmaceuticals' revenue grows nine per cent to £2.47bn as profit boomsFebruary 26, 2025 | msn.comHikma Pharmaceuticals advances Friday, outperforms marketFebruary 21, 2025 | marketwatch.comHikma Pharmaceuticals (LON:HIK) Shares Pass Above 200-Day Moving Average - Time to Sell?Hikma Pharmaceuticals (LON:HIK) Shares Cross Above 200-Day Moving Average - Should You Sell?February 20, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Sets New 52-Week High - Time to Buy?Hikma Pharmaceuticals (LON:HIK) Reaches New 12-Month High - Time to Buy?February 12, 2025 | marketbeat.comInvesting in Hikma Pharmaceuticals (LON:HIK) five years ago would have delivered you a 38% gainFebruary 11, 2025 | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) Hits New 1-Year High - Here's What HappenedHikma Pharmaceuticals (LON:HIK) Reaches New 12-Month High - Still a Buy?February 6, 2025 | marketbeat.comGuardant Health & ADPHC in deal to debut non-invasive blood-based CRC testJanuary 30, 2025 | markets.businessinsider.comBerenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) StockBerenberg Bank boosted their price objective on Hikma Pharmaceuticals from GBX 2,400 ($29.88) to GBX 2,560 ($31.87) and gave the stock a "buy" rating in a research note on Wednesday.January 30, 2025 | marketbeat.comGuardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening ProgramJanuary 30, 2025 | finance.yahoo.comBasilea Pharmaceutica AG: Strong sales growth for Cresemba and Zevtera trigger further milestone payments to BasileaJanuary 28, 2025 | finanznachrichten.deHikma Pharmaceuticals (LON:HIK) Reaches New 52-Week High - What's Next?Hikma Pharmaceuticals (LON:HIK) Reaches New 52-Week High - Here's WhyJanuary 27, 2025 | marketbeat.comEmergent seeking to reverse fortunes and become a major overdose treatment playerJanuary 23, 2025 | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) Reaches New 12-Month Low - What's Next?Hikma Pharmaceuticals (LON:HIK) Hits New 12-Month Low - Should You Sell?January 23, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above 200 Day Moving Average - Here's What HappenedHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?January 18, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?January 18, 2025 | marketbeat.comEmergent BioSolutions gains exclusive commercial rights to KLOXXADOJanuary 14, 2025 | msn.comEBS obtains rights to Hikma's Kloxxado naloxone sprayJanuary 14, 2025 | msn.comHikma Pharma Inks Exclusive Commercial Deal With Emergent BioSolutions For KLOXXADO Nasal Spray 8 MgJanuary 14, 2025 | markets.businessinsider.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedJanuary 10, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200-Day Moving Average - Here's WhyHikma Pharmaceuticals (LON:HIK) Shares Pass Above 200 Day Moving Average - Here's WhyJanuary 10, 2025 | marketbeat.comFDA Announcement: The First Generic GLP-1 Shot Has Just Been ApprovedJanuary 2, 2025 | msn.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200 Day Moving Average - Here's WhyHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comFDA Approves First Generic Liraglutide Injection, Ushering in a New Era for Type 2 Diabetes TreatmentDecember 30, 2024 | msn.comIs Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?December 29, 2024 | msn.comFDA approves Hikma’s generic version of Novo’s diabetes drug VictozaDecember 25, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200-Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average - What's Next?December 25, 2024 | marketbeat.comFDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?December 23, 2024 | yahoo.comThere’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is comingDecember 23, 2024 | msn.comUS FDA revokes authorization for four COVID treatmentsDecember 23, 2024 | reuters.comUS FDA approves Hikma's generic version of Novo's diabetes drug VictozaDecember 23, 2024 | reuters.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average - What's Next?December 17, 2024 | marketbeat.comBTIG Downgrades Carisma Therapeutics (CARM)December 11, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Here's WhyHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Should You Sell?December 7, 2024 | marketbeat.comHikma Pharmaceuticals rises Monday, still underperforms marketNovember 12, 2024 | marketwatch.com Remove Ads Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Media Mentions By Week HIK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HIK News Sentiment▼0.750.78▲Average Medical News Sentiment HIK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HIK Articles This Week▼12▲HIK Articles Average Week Remove Ads Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HUTCHMED News Indivior News Alliance Pharma News Allergy Therapeutics News Animalcare Group News Venture Life Group News ECO Animal Health Group News Shield Therapeutics News Chill Brands Group News Celadon Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:HIK) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
